Novo Nordisk said on Monday it has launched its popular obesity drug Wegovy in China, the world's second-largest ...

Novo Nordisk said on Monday it has launched its popular obesity drug Wegovy in China, the world's second-largest ...

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...

About 400 people marched to the South African headquarters of Novo Nordisk A/S in Johannesburg this week demanding greater ...

Are you a print subscriber? Activate your account. By Mark Pappas - 11 min 42 sec ago 52 min 1 sec ago By Garett Sloane - 2 ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Novo Nordisk A/S is launching its top-selling Wegovy obesity drug in China at a fraction of the US price, a key step in unlocking a big, fast-growing market for its blockbuster franchise.

Novo Nordisk's Wegovy launch in China begins in Shanghai at $194 per four-injection pack, significantly cheaper than U.S.

Novo Nordisk (NVO) has released an update. Don't Miss our Black Friday Offers: Novo Nordisk has launched a share repurchase program, aiming to buy back B shares worth up to DKK 20 billion over a ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

Novo Nordisk (NVO) reportedly plans to phase out production of human insulin pens while it ramps up production of other ...